Stock UROV UROVANT SCIENCES LTD.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Urovant Sciences Ltd.

Equities

UROV

BMG9381B1081

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Urovant Sciences and Pierre Fabre Médicament Enters into Exclusive License Agreement
CI
Urovant Sciences Ltd. Presents New Data from EMPOWUR Study, Advancing Knowledge of the Treatment of Overactive Bladder at the 2022 American Urological Association Meeting
CI
Urovant Sciences Presents Interim Data from Phase 2a Study of Investigational Novel Gene Therapy, URO-902, Supporting Safety, Tolerability, and Efficacy Endpoints
CI
Urovant Sciences Announces the Publication of A New, Post-Hoc Analysis of Data from the Phase 3 EMPOWUR Trial of GEMTESA 75 Mg in the International Journal of Clinical Practice
CI
Urovant Sciences to Present Interim Data from Phase 2a Study of Potential Novel Gene Therapy, URO-902, and New Analyses of Data from Phase 3 EMPOWUR Extension Trial of GEMTESA® (vibegron) 75 mg at 2022 American Urological Association Annual Meeting
BU
Urovant Sciences Announces Management Changes
CI
Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902
BU
Urovant Sciences Announces Publication in Advances in Therapy of Analyses of Patient-Perceived Meaningfulness of Improvement in Symptom Reduction for Overactive Bladder Patients Treated with GEMTESA® (vibegron) 75 mg
BU
Urovant Sciences Announces Publication in Blood Pressure Monitoring of Positive Ambulatory Blood Pressure Study Results for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients
BU
Urovant Sciences Ltd. Announces Executive Changes
CI
Urovant Sciences Names Betzy Estrada as Executive VP and Chief Human Resources Officer
CI
Urovant Sciences to Present Key Data for GEMTESA® 75 Mg At the 2021 Annual Meeting of the American Urological Association
CI
Urovant Sciences Ltd.(NasdaqGS:UROV) dropped from S&P TMI Index
CI
UROVANT SCIENCES LTD. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Urovant Sciences Ltd. Announces Board Changes
CI
Urovant Sciences Ltd.(NasdaqGS:UROV) dropped from NASDAQ Composite Index
CI
Sumitovant Biopharma Ltd. completed the acquisition of the remaining 27.6% stake in Urovant Sciences Ltd..
CI
Transcript : Urovant Sciences Ltd. - Shareholder/Analyst Call
Urovant Sciences : Posts Wider Fiscal Q3 Net Loss
MT
Urovant Sciences Ltd. Reports Earnings Results for the Third Quarter Ended December 31, 2020
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. UROV Stock
  4. News Urovant Sciences Ltd.